Source: Eur Respir J 2012; 39: 677-684
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Tsai T-H., Su K-Y., Wu S-G., Chang Y-L., Luo S-C., Jan I-S., Yu C-J., Yu S-L., Shih J-Y., Yang P-C.. RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer. Eur Respir J 2012; 39: 677-684

Member's Comments

No comment yet.

Related content which might interest you: Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis Source: Eur Respir J 2013; 41: 417-424 Year: 2013 Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma Source: Eur Respir J 2008; 32: 924-930 Year: 2008 Survival of lung adenocarcinoma patients with malignant pleural effusion Source: Eur Respir J 2013; 41: 1409-1418 Year: 2013 Oncodrivers in malignant pleural effusions associated with non-small cell lung cancer Source: Virtual Congress 2020 – Interventional pulmonology: the pleura and bronchoscopic treatment of emphysema Year: 2020 Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma Year: 2006 Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation Source: Eur Respir J 2011; 37: 624-631 Year: 2011 EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up Source: Eur Respir J 2009; 33: 436-440 Year: 2009 Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer Source: Eur Respir J 2011; 38: 903-910 Year: 2011 Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours Year: 2015 Tumor-derived tumor necrosis factor-α promotes Lewis lung cancer-induced malignant pleural effusions in mice Source: Annual Congress 2006 - Molecular pathology and genetics of lung cancer Year: 2006 Diagnostic significance of ADAM8 in non-small cell lung cancer and malignant pleural effusion Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology Year: 2008 High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer Source: ERJ Open Res, 7 (1) 00787-2020; 10.1183/23120541.00787-2020 Year: 2021 The diagnosis and incidence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation in lung adenocarcinoma Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Sensitivity of PD-L1 analysis from pleural effusion in non-small cell lung cancer Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 186-196 Year: 2010 Management of EGFR mutated nonsmall cell lung carcinoma patients Source: Eur Respir J 2015; 45: 1132-1141 Year: 2015 The prediction of risk factors of tyrosine kinase inhibitor-induced pneumonitis in non-small cell lung cancer Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Clinical and biological prognostic factors in malignant pleural effusion (MPE) secondary to breast cancer Source: Annual Congress 2005 - What's new in the pleura Year: 2005